Crinetics Pharmaceuticals (CRNX)
US Market

Crinetics Pharmaceuticals (CRNX) Stock Price & Analysis


CRNX Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$15.23 - $31.00
Previous Close$28.69
Average Volume (3M)1.33M
Market Cap
Enterprise ValueN/A
Total Cash (Recent Filing)$264.53M
Total Debt (Recent Filing)$2.56M
Price to Earnings (P/E)-8.4
Nov 14, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.41
Shares Outstanding54,686,550
10 Day Avg. Volume2,245,942
30 Day Avg. Volume1,329,742
Standard Deviation0.14
Financial Highlights & Ratios
Price to Book (P/B)6.37
Price to Sales (P/S)1588.01
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Price Target Upside76.38% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9



Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Insights

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Crinetics Pharmaceuticals’s price range in the past 12 months?
Crinetics Pharmaceuticals lowest stock price was $15.23 and its highest was $31.00 in the past 12 months.
    What is Crinetics Pharmaceuticals’s market cap?
    Currently, no data Available
    When is Crinetics Pharmaceuticals’s upcoming earnings report date?
    Crinetics Pharmaceuticals’s upcoming earnings report date is Nov 14, 2023 which is in 47 days.
      How were Crinetics Pharmaceuticals’s earnings last quarter?
      Crinetics Pharmaceuticals released its earnings results on Aug 08, 2023. The company reported -$0.94 earnings per share for the quarter, missing the consensus estimate of -$0.866 by -$0.074.
        Is Crinetics Pharmaceuticals overvalued?
        According to Wall Street analysts Crinetics Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Crinetics Pharmaceuticals pay dividends?
          Crinetics Pharmaceuticals does not currently pay dividends.
          What is Crinetics Pharmaceuticals’s EPS estimate?
          Crinetics Pharmaceuticals’s EPS estimate is -$0.91.
            How many shares outstanding does Crinetics Pharmaceuticals have?
            Crinetics Pharmaceuticals has 66,128,200 shares outstanding.
              What happened to Crinetics Pharmaceuticals’s price movement after its last earnings report?
              Crinetics Pharmaceuticals reported an EPS of -$0.94 in its last earnings report, missing expectations of -$0.866. Following the earnings report the stock price went down -3.889%.
                Which hedge fund is a major shareholder of Crinetics Pharmaceuticals?
                Among the largest hedge funds holding Crinetics Pharmaceuticals’s share is Driehaus Capital Management LLC. It holds Crinetics Pharmaceuticals’s shares valued at 95M.


                  Crinetics Pharmaceuticals Stock Smart Score

                  The Crinetics Pharmaceuticals stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Crinetics Pharmaceuticals

                  Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. It is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.


                  Top 5 ETFs holding CRNX

                  Market Value
                  Smart Score
                  Vanguard Total Stock Market ETF
                  iShares Core S&P Total U.S. Stock Market ETF
                  Schwab U.S. Broad Market ETF
                  iShares Russell 3000 ETF
                  Vanguard Russell 3000 ETF
                  Up to five ETFs with an Outperform Smart Score that hold CRNX. The ETFs are listed according to market value of CRNX within the ETF

                  Forecast EPS vs Actual EPS

                  Similar Stocks
                  Price & Change
                  Voyager Therapeutics
                  Revance Therapeutics
                  Rocket Pharmaceuticals
                  Mirati Therapeutics

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis